Premium
Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B‐cell leukemia
Author(s) -
Arora Mansi,
Kaul Deepak,
Varma Neelam
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25387
Subject(s) - deubiquitinating enzyme , mutant , lymphoblastic leukemia , regulator , cancer research , medicine , leukemia , ubiquitin , gene , genetics , biology , immunology
The Deubiquitinating enzyme, Cylindromatosis (CYLD), has been established as a crucial regulator of B‐cells. The present study was addressed to identify the nature of CYLD‐dependent RNomics in patients of pediatric age group with B‐ALL. The study revealed the presence of a novel mutant CYLD of 55 kDa in these patients. The mutant CYLD displayed its ability to restrict the cells in G2 phase of cell cycle, down‐regulate PLK‐1 and block the nuclear translocation of BCL3. Based upon these results, we propose that this mutant CYLD has the capacity to act as a differential marker characteristic of B‐cell lymphoblastic leukemia. Pediatr Blood Cancer 2015;62:1066–1069. © 2015 Wiley Periodicals, Inc.